BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen FC, Liao YC, Huang JM, Lin CH, Chen YY, Dou HY, Hsiung CA. Pros and cons of the tuberculosis drugome approach--an empirical analysis. PLoS One 2014;9:e100829. [PMID: 24971632 DOI: 10.1371/journal.pone.0100829] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Santos P, López-Vallejo F, Soto CY. In silico approaches and chemical space of anti-P-type ATPase compounds for discovering new antituberculous drugs. Chem Biol Drug Des 2017;90:175-87. [PMID: 28111912 DOI: 10.1111/cbdd.12950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Chetty S, Ramesh M, Singh-Pillay A, Soliman ME. Recent advancements in the development of anti-tuberculosis drugs. Bioorg Med Chem Lett 2017;27:370-86. [PMID: 28017531 DOI: 10.1016/j.bmcl.2016.11.084] [Cited by in Crossref: 67] [Cited by in F6Publishing: 49] [Article Influence: 11.2] [Reference Citation Analysis]
3 Ekins S, Madrid PB, Sarker M, Li SG, Mittal N, Kumar P, Wang X, Stratton TP, Zimmerman M, Talcott C, Bourbon P, Travers M, Yadav M, Freundlich JS. Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. PLoS One 2015;10:e0141076. [PMID: 26517557 DOI: 10.1371/journal.pone.0141076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
4 Miró-Canturri A, Vila-Domínguez A, Caretero-Ledesma M, Ayerbe-Algaba R, Pachón J, Jiménez-Mejías ME, Smani Y. Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections. Microbiol Spectr 2021;9:e0040321. [PMID: 34668743 DOI: 10.1128/Spectrum.00403-21] [Reference Citation Analysis]
5 Miró-Canturri A, Ayerbe-Algaba R, Vila-Domínguez A, Jiménez-Mejías ME, Pachón J, Smani Y. Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli. Antibiotics (Basel) 2021;10:336. [PMID: 33810067 DOI: 10.3390/antibiotics10030336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ouyang Q, Zhang K, Lin D, Feng CG, Cai Y, Chen X. Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy. mSphere 2020;5:e00124-20. [PMID: 32269154 DOI: 10.1128/mSphere.00124-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
7 Montoya MC, Krysan DJ. Repurposing Estrogen Receptor Antagonists for the Treatment of Infectious Disease. mBio 2018;9:e02272-18. [PMID: 30563895 DOI: 10.1128/mBio.02272-18] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
8 Feng X, Zhu W, Schurig-Briccio LA, Lindert S, Shoen C, Hitchings R, Li J, Wang Y, Baig N, Zhou T, Kim BK, Crick DC, Cynamon M, McCammon JA, Gennis RB, Oldfield E. Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci U S A 2015;112:E7073-82. [PMID: 26644565 DOI: 10.1073/pnas.1521988112] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
9 Al-Janabi AAHS. Repurposing of Tamoxifen Against the Oral Bacteria. Turk J Pharm Sci 2021;18:68-74. [PMID: 33634670 DOI: 10.4274/tjps.galenos.2019.23500] [Reference Citation Analysis]